FDA regulators have issued a warning to ImmunityBio, a biotechnology company headed by billionaire Dr. Patrick Soon-Shiong, following misleading statements about their cancer treatment drug, Anktiva. The FDA's letter specifically criticized claims made during a podcast episode and a TV advertisement suggesting that the drug may treat, cure, or prevent several types of cancers beyond its approved use for bladder cancer.
Dr. Soon-Shiong's controversial assertions lined up with a call to action on his podcast, where he labeled Anktiva as 'the most important molecule that could cure cancer,' raising alarms about the implications of such statements. Following the FDA's warning, shares of ImmunityBio plummeted by over 24%.
The FDA's letter, addressed to the company's CEO, Richard Adcock, emphasized that such statements contravene federal regulations which mandate accurate and balanced depictions of drugs regarding their risks and benefits. Notably, the communications failed to include important information about potential side effects, including urinary tract infections and fevers, which could mislead consumers.
In response, ImmunityBio expressed its intent to work collaboratively with the FDA to rectify the issues raised, highlighting the seriousness with which they take the regulatory warning. The FDA has given the company 15 days to address these concerns in writing.
The issue underscores the ongoing scrutiny faced by drug manufacturers and the responsibility of industry leaders to ensure compliance with marketing regulations, especially as the rise in unapproved claims poses risks to public health. As part of heightened regulatory measures initiated during the previous administration, the FDA has intensified its oversight on drug advertisement practices, ensuring that public communications reflect a truthful account of drug capabilities.
